Boston Scientific announced an agreement to acquire Penumbra in a cash-and-stock transaction valued at 14.5 billion. Under the terms, Penumbra shareholders will receive approximately 73 percent cash and 27 percent in Boston Scientific equity. The deal expands Boston Scientific’s presence in high-growth neurovascular and peripheral vascular thrombectomy markets, where Penumbra delivered 21–24 percent revenue growth in preliminary fourth-quarter 2025 results. Management forecasts that the acquisition will dilute earnings by roughly 6–8 cents per share in year one, moving toward neutral to modestly accretive contribution by year two, driven by cost synergies and cross-selling opportunities.

Citigroup upgraded Boston Scientific to a Buy rating on January 14, 2026, citing the company’s deepening exposure to higher-margin franchises and a constructive product pipeline. This upgrade followed Boston Scientific’s presentation at the 44th Annual J.P. Morgan Healthcare Conference, where executives outlined a roadmap for electrophysiology expansion and digital health initiatives. Analysts highlighted that the WATCHMAN franchise’s double-digit growth and broader capital spending trends in hospitals underpin a favorable earnings trajectory, lifting investor expectations for margin expansion over the next 12 to 18 months.

Boston Scientific reported a year-over-year improvement in operating margins, driven by strong performance in electrophysiology and WATCHMAN devices, which now account for more than 15 percent of total revenue. The shift toward these higher-margin businesses supported free cash flow stability, with the company generating over 4 billion in cash from operations in 2025. In parallel, Boston Scientific entered into a definitive agreement to acquire Valencia Technologies, a specialist in bladder-dysfunction devices, including the eCoin System. This move is expected to broaden the company’s urology portfolio and address a potential 30 million-patient market in the U.S., enhancing long-term revenue diversity.